Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

$LH
Medical Specialities
Health Care
Get the next $LH alert in real time by email
lh-20250108
January 8, 20250000920148false00009201482025-01-082025-01-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

January 8, 2025
(Date of earliest event reported)
LABCORP HOLDINGS INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware1-1135399-2588107
(State or other jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

358 South Main Street 
Burlington,North Carolina27215
(Address of principal executive offices)(Zip Code)
(Registrant’s telephone number including area code) 336-229-1127
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act.
Title of each classTrading SymbolName of exchange on which registered
Common Stock, $0.10 par valueLHNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).             
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01Regulation FD Disclosure
Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2024 before the market opens on Thursday, February 6, 2025, and will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website.
Item 9.01
Financial Statements and Exhibits.

ExhibitExhibit Name
Exhibit 99.1





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABCORP HOLDINGS INC.
Registrant

Date: January 8, 2025
By:/s/ SANDRA VAN DER VAART
 Sandra van der Vaart
  Executive Vice President, Chief Legal Officer and Corporate Secretary

Get the next $LH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LH

DatePrice TargetRatingAnalyst
3/4/2025$250.00 → $300.00Neutral → Buy
Citigroup
1/7/2025$260.00 → $265.00In-line → Outperform
Evercore ISI
12/10/2024$265.00 → $275.00Buy
Jefferies
10/30/2024Hold → Buy
HSBC Securities
10/1/2024$235.00Neutral
Piper Sandler
3/25/2024$250.00Hold → Buy
Argus
2/26/2024$260.00Outperform
Leerink Partners
2/9/2024$240.00In-line
Evercore ISI
More analyst ratings

$LH
Press Releases

Fastest customizable press release news feed in the world

See more
  • Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

    Transaction to extend Labcorp's leadership in oncology and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI, March 11, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health. Through this transaction, Labcorp will acquire Bi

    $LH
    $OPK
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • Labcorp Announces Clinical Availability of Liquid Biopsy Test to Guide Personalized Treatment Plans for Patients with Advanced Solid Tumors

    Labcorp® Plasma CompleteTM offers oncologists a highly sensitive and specific genomic profiling solution from a simple blood draw BURLINGTON, N.C., Feb. 24, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today the clinical availability of Labcorp® Plasma CompleteTM, a circulating tumor DNA (ctDNA)-based comprehensive genomic profiling solution for patients with advanced solid tumors. The liquid biopsy test enables oncologists to perform comprehensive genomic profiling to inform personalized treatment decisions – all from a simple blood draw.

    $LH
    Medical Specialities
    Health Care
  • Labcorp Announces 2024 Fourth Quarter and Full Year Results

    Company Provides 2025 Guidance Results from Continuing Operations versus last year:Revenue: Q4 of $3.33 billion vs $3.03 billion; Full year of $13.01 billion vs $12.16 billionDiluted EPS: Q4 of $1.70 vs $(1.95); Full year of $8.84 vs $4.33Adjusted EPS: Q4 of $3.45 vs $3.30; Full year of $14.57 vs $13.56Free Cash Flow: Q4 of $665.1 million vs $412.4 million; Full year of $1.10 billion vs $748.7 millionAnnounced 10 transactions and launched new innovative tests meeting significant unmet medical needs in key specialty areas in full year 2024Full-Year 2025 Guidance:Revenue of $13.88 billion to $14.05 billion; midpoint growth of 7.4%Adjusted EPS of $15.60 to $16.40; midpoint growth of 9.8%Free Ca

    $LH
    Medical Specialities
    Health Care

$LH
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$LH
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$LH
SEC Filings

See more

$LH
Leadership Updates

Live Leadership Updates

See more
  • Labcorp CFO Glenn Eisenberg Announces Plans to Retire

    Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.

    $BGNE
    $LH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
  • Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

    Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns

    $ENV
    $LH
    $MASI
    $MSCI
    Business Services
    Consumer Discretionary
    Medical Specialities
    Health Care
  • Advantage Healthcare Holdings Appoints Dinak Nair as Chief Executive Officer

    Advantage Healthcare Holdings ("Advantage" or the "Company"), a regional leader in providing patient-centered healthcare through managing and operating Comprehensive Outpatient Rehabilitation Facilities and Sleep Centers, announced that its Board of Directors has named Dinak (Dino) Nair as its Chief Executive Officer. Mr. Nair assumed leadership of the Company from the prior CEO, Ryan Tong, on September 1, 2024. Mr. Nair brings over 20 years of business experience, with more than a decade as a mission-driven leader growing businesses in the healthcare market, especially in homecare, home medical equipment, diagnostic laboratory, and health system partnerships. Mr. Nair most recently served

    $AHCO
    $LH
    Medical/Nursing Services
    Health Care
    Medical Specialities

$LH
Financials

Live finance-specific insights

See more
  • Labcorp Announces 2024 Fourth Quarter and Full Year Results

    Company Provides 2025 Guidance Results from Continuing Operations versus last year:Revenue: Q4 of $3.33 billion vs $3.03 billion; Full year of $13.01 billion vs $12.16 billionDiluted EPS: Q4 of $1.70 vs $(1.95); Full year of $8.84 vs $4.33Adjusted EPS: Q4 of $3.45 vs $3.30; Full year of $14.57 vs $13.56Free Cash Flow: Q4 of $665.1 million vs $412.4 million; Full year of $1.10 billion vs $748.7 millionAnnounced 10 transactions and launched new innovative tests meeting significant unmet medical needs in key specialty areas in full year 2024Full-Year 2025 Guidance:Revenue of $13.88 billion to $14.05 billion; midpoint growth of 7.4%Adjusted EPS of $15.60 to $16.40; midpoint growth of 9.8%Free Ca

    $LH
    Medical Specialities
    Health Care
  • LABCORP DECLARES QUARTERLY DIVIDEND

    BURLINGTON, N.C., Jan. 8, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 12, 2025, to stockholders of record as of the close of business on February 27, 2025. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and co

    $LH
    Medical Specialities
    Health Care
  • Labcorp to Announce Fourth Quarter Financial Results on February 6, 2025

    BURLINGTON, N.C., Jan. 8, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2024 before the market opens on Thursday, February 6, 2025. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Particip

    $LH
    Medical Specialities
    Health Care

$LH
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more